|
|
Advances in the Study of Antibody Composition and Targets of ADC Drugs |
ZENG Hong-ye,NING Wen-jing,LUO Wen-xin**() |
National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, China |
|
|
Abstract Antibody drug conjugates (ADCs) are a type of novel anti-tumor drugs, which are composed of three components: antibody, cytotoxic drugs and linker. Compared with traditional cytotoxic drugs, ADC has the ability to specifically target tumor cell and release small molecular drugs to achieve the effect of tumor-specific killing, showing good therapeutic potential in clinical practice. Particularly, the antibody of ADC can accurately deliver small molecule cytotoxin to the tumor by combining with targeted antigens on the surface of tumor cell, which is one of the core elements affecting the efficacy of ADCs. The review outlines advances in the study of antibody composition and targets of ADC drugs.
|
Received: 29 November 2021
Published: 17 June 2022
|
|
Corresponding Authors:
Wen-xin LUO
E-mail: wxluo@xmu.edu.cn
|
|
|
[1] |
Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nature Reviews Cancer, 2008, 8 (6): 473-480.
doi: 10.1038/nrc2394
pmid: 18469827
|
|
|
[2] |
Joubert N, Beck A, Dumontet C, et al. Antibody-drug conjugates: the last decade. Pharmaceuticals (Basel, Switzerland), 2020, 13(9): 245.
|
|
|
[3] |
Iyer U, Kadambi V J. Antibody drug conjugates:Trojan horses in the war on cancer. Journal of Pharmacological and Toxicological Methods, 2011, 64(3): 207-212.
doi: 10.1016/j.vascn.2011.07.005
pmid: 21843648
|
|
|
[4] |
Yu J F, Song Y P, Tian W Z. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. Journal of Hematology & Oncology, 2020, 13(1): 45.
|
|
|
[5] |
Jin Y M, Schladetsch M A, Huang X T, et al. Stepping forward in antibody-drug conjugate development. Pharmacology & Therapeutics, 2022, 229: 107917.
|
|
|
[6] |
Dean A Q, Luo S, Twomey J D, et al. Targeting cancer with antibody-drug conjugates: promises and challenges. mAbs, 2021, 13(1): 1951427.
doi: 10.1080/19420862.2021.1951427
|
|
|
[7] |
Gomes-da-Silva L C, Kepp O, Kroemer G. Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death. OncoImmunology, 2020, 9(1): 1841393.
doi: 10.1080/2162402X.2020.1841393
|
|
|
[8] |
Caimi P F, Ai W Y, Alderuccio J P, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology, 2021, 22(6): 790-800.
doi: 10.1016/S1470-2045(21)00139-X
|
|
|
[9] |
Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC 48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond), 2021, 41(11): 1173-1182.
|
|
|
[10] |
BusinessWire. Seagen and Genmab announce FDA accelerated approval for TIVDAKTM tisotumab vedotin-tftv in previously treated recurrent or metastatic cervical cancer. [2021-09-20]. https://www.businesswire.com/news/home/20210920005921/en/.
|
|
|
[11] |
Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nature Reviews Drug Discovery, 2017, 16 (5): 315-337.
doi: 10.1038/nrd.2016.268
|
|
|
[12] |
Walsh S J, Bargh J D, Dannheim F M, et al. Site-selective modification strategies in antibody-drug conjugates. Chemical Society Reviews, 2021, 50(2): 1305-1353.
doi: 10.1039/D0CS00310G
|
|
|
[13] |
Kim E G, Kim K M. Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomolecules & Therapeutics, 2015, 23 (6): 493-509.
|
|
|
[14] |
Christiansen J, Rajasekaran A K. Biological impediments to monoclonal antibody-based cancer immunotherapy. Molecular Cancer Therapeutics, 2004, 3(11): 1493-1501.
pmid: 15542788
|
|
|
[15] |
Labrijn A F, Janmaat M L, Reichert J M, et al. Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery, 2019, 18 (8): 585-608.
doi: 10.1038/s41573-019-0028-1
pmid: 31175342
|
|
|
[16] |
Carter P J, Lazar G A. Next generation antibody drugs: pursuit of the ’high-hanging fruit. Nature Reviews Drug Discovery, 2018, 17 (3): 197-223.
doi: 10.1038/nrd.2017.227
pmid: 29192287
|
|
|
[17] |
Hamblett K J, Hammond P W, Barnscher S D, et al. ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers. Cancer Research, 2018, 78(13 Supplement): 3914.
|
|
|
[18] |
DaSilva J O, Yang K T, Surriga O, et al. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. Molecular Cancer Therapeutics, 2021, 20(10): 1966-1976.
doi: 10.1158/1535-7163.MCT-21-0009
pmid: 34315762
|
|
|
[19] |
Lee N K, Su Y, Bidlingmaier S, et al. Manipulation of cell-type selective antibody internalization by a guide-effector bispecific design. Molecular Cancer Therapeutics, 2019, 18(6): 1092-1103.
doi: 10.1158/1535-7163.MCT-18-1313
|
|
|
[20] |
Chomet M, Schreurs M, Nguyen M, et al. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89 Zr-immuno-PET in xenograft bearing mice. Theranostics, 2020, 10(13): 5815-5828.
doi: 10.7150/thno.44334
|
|
|
[21] |
Johnson M, El-Khoueiry A, Hafez N, et al. Phase I, first-in-human study of the probody therapeutic CX-2029 in adults with advanced solid tumor malignancies. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2021, 27(16): 4521-4530.
doi: 10.1158/1078-0432.CCR-21-0194
|
|
|
[22] |
Deonarain M P, Xue Q. Tackling solid tumour therapy with small-format drug conjugates. Antibody Therapeutics, 2020, 3(4): 237-245.
doi: 10.1093/abt/tbaa024
pmid: 33928231
|
|
|
[23] |
Liu M M, Li L, Jin D, et al. Nanobody:a versatile tool for cancer diagnosis and therapeutics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13(4): e1697.
|
|
|
[24] |
Wu T T, Liu J B, Liu M M, et al. A nanobody-conjugated DNA nanoplatform for targeted platinum-drug delivery. Angewandte Chemie International Edition, 2019, 58(40): 14224-14228.
|
|
|
[25] |
Liu M M, Zhu Y, Wu T T, et al. Nanobody-ferritin conjugate for targeted photodynamic therapy. Chemistry: A European Journal, 2020, 26(33): 7442-7450.
doi: 10.1002/chem.202000075
|
|
|
[26] |
Fang T, Duarte J N, Ling J J, et al. Structurally defined αMHC-II nanobody-drug conjugates: a therapeutic and imaging system for B-cell lymphoma. Angewandte Chemie (International Ed in English), 2016, 55(7): 2416-2420.
doi: 10.1002/anie.201509432
|
|
|
[27] |
Xenaki K T, Dorrestijn B, Muns J A, et al. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Theranostics, 2021, 11(11): 5525-5538.
doi: 10.7150/thno.57510
|
|
|
[28] |
Baral T N, Magez S, Stijlemans B, et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nature Medicine, 2006, 12 (5): 580-584.
pmid: 16604085
|
|
|
[29] |
Collins D M, Bossenmaier B, Kollmorgen G, et al. Acquired resistance to antibody-drug conjugates. Cancers, 2019, 11(3): 394.
doi: 10.3390/cancers11030394
|
|
|
[30] |
Turajlic S, Sottoriva A, Graham T, et al. Resolving genetic heterogeneity in cancer. Nature Reviews Genetics, 2019, 20 (7): 404-416.
doi: 10.1038/s41576-019-0114-6
pmid: 30918367
|
|
|
[31] |
Stokke J L, Bhojwani D. Antibody-drug conjugates for the treatment of acute pediatric leukemia. Journal of Clinical Medicine, 2021, 10(16): 3556.
doi: 10.3390/jcm10163556
|
|
|
[32] |
Costa R L B, Czerniecki B J. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. Npj Breast Cancer, 2020, 6: 10.
doi: 10.1038/s41523-020-0153-3
|
|
|
[33] |
Shitara K, Bang Y J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. The New England Journal of Medicine, 2020, 382(25): 2419-2430.
doi: 10.1056/NEJMoa2004413
pmid: 32469182
|
|
|
[34] |
Siena S, Bartolomeo M D, Raghav K, et al. rastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. The Lancet Oncology, 2021, 22(6): 779-789.
doi: 10.1016/S1470-2045(21)00086-3
|
|
|
[35] |
Li B T, Shen R L, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2018, 36(24): 2532-2537.
doi: 10.1200/JCO.2018.77.9777
|
|
|
[36] |
Sheng X N, Yan X Q, Wang L, et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2021, 27(1): 43-51.
doi: 10.1158/1078-0432.CCR-20-2488
|
|
|
[37] |
Modi S N, Park H, Murthy R K, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase ib study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2020, 38(17): 1887-1896.
doi: 10.1200/JCO.19.02318
|
|
|
[38] |
Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. The Lancet Oncology, 2019, 20(6): 827-836.
doi: 10.1016/S1470-2045(19)30088-9
|
|
|
[39] |
Kang J C, Sun W, Khare P, et al. Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy. Nature Biotechnology, 2019, 37 (5): 523-526.
doi: 10.1038/s41587-019-0073-7
|
|
|
[40] |
Li J Y, Perry S R, Muniz-Medina V, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell, 2016, 29(1): 117-129.
doi: 10.1016/j.ccell.2015.12.008
|
|
|
[41] |
Nordstrom J L, Gorlatov S, Zhang W J, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Research, 2011, 13(6): R123.
doi: 10.1186/bcr3069
|
|
|
[42] |
Bang Y J, Giaccone G, Im S A, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. . Annals of Oncology, 2017, 28(4): 855-861.
doi: 10.1093/annonc/mdx002
pmid: 28119295
|
|
|
[43] |
Kang X H, Zhou L, Jian Y M, et al. Effectiveness of antibody-drug conjugate (ADC): results of in vitro and in vivo studies. Medical Science Monitor, 2018, 24: 1408-1416.
doi: 10.12659/MSM.908971
|
|
|
[44] |
Gan H K, Burgess A W, Clayton A H A, et al. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Research, 2012, 72(12): 2924-2930.
doi: 10.1158/0008-5472.CAN-11-3898
|
|
|
[45] |
Cleary J M, Reardon D A, Azad N, et al. A phase 1 study of ABT-806 in subjects with advanced solid tumors. Investigational New Drugs, 2015, 33(3): 671-678.
doi: 10.1007/s10637-015-0234-6
pmid: 25895099
|
|
|
[46] |
Chia P L, Parakh S, Tsao M S, et al. Targeting and efficacy of novel MAb806-antibody-drug conjugates in malignant mesothelioma. Pharmaceuticals (Basel, Switzerland), 2020, 13(10): 289.
|
|
|
[47] |
Phillips A C, Boghaert E R, Vaidya K S, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Molecular Cancer Therapeutics, 2016, 15(4): 661-669.
doi: 10.1158/1535-7163.MCT-15-0901
pmid: 26846818
|
|
|
[48] |
Park K, Haura E B, Leighl N B, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2021, 39(30): 3391-3402.
doi: 10.1200/JCO.21.00662
|
|
|
[49] |
Goldenberg D M, Cardillo T M, Govindan S V, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget, 2015, 6(26): 22496-22512.
pmid: 26101915
|
|
|
[50] |
Bardia A, Hurvitz S A, Tolaney S M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. The New England Journal of Medicine, 2021, 384(16): 1529-1541.
doi: 10.1056/NEJMoa2028485
|
|
|
[51] |
TROP2 ADC intrigues in NSCLC. Cancer Discovery, 2021, 11(5): OF5.
|
|
|
[52] |
Scaranti M, Cojocaru E, Banerjee S, et al. Exploiting the folate receptor α in oncology. Nature Reviews Clinical Oncology, 2020, 17 (6): 349-359.
doi: 10.1038/s41571-020-0339-5
pmid: 32152484
|
|
|
[53] |
Moore K N, Oza A M, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Annals of Oncology, 2021, 32(6): 757-765.
doi: 10.1016/j.annonc.2021.02.017
pmid: 33667670
|
|
|
[54] |
Haikala H M, Jänne P A. Thirty years of HER3: from basic biology to therapeutic interventions. Clinical Cancer Research, 2021, 27(13): 3528-3539.
doi: 10.1158/1078-0432.CCR-20-4465
pmid: 33608318
|
|
|
[55] |
Yonesaka K. HER2-/ HER3-targeting antibody-drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors. Cancers, 2021, 13(5): 1047.
doi: 10.3390/cancers13051047
|
|
|
[56] |
Powles T, Rosenberg J E, Sonpavde G P, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. The New England Journal of Medicine, 2021, 384(12): 1125-1135.
doi: 10.1056/NEJMoa2035807
|
|
|
[57] |
M-Rabet M, Cabaud O, Josselin E, et al. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Annals of Oncology, 2017, 28(4): 769-776.
doi: 10.1093/annonc/mdw678
pmid: 27998973
|
|
|
[58] |
Yap M L, McFadyen J D, Wang X W, et al. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. Theranostics, 2019, 9(4): 1154-1169.
doi: 10.7150/thno.29146
|
|
|
[59] |
Szot C, Saha S, Zhang X M, et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. The Journal of Clinical Investigation, 2018, 128(7): 2927-2943.
doi: 10.1172/JCI120481
|
|
|
[60] |
Breij E C W, de Goeij B E C G, Verploegen S, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Research, 2014, 74(4): 1214-1226.
doi: 10.1158/0008-5472.CAN-13-2440
|
|
|
[61] |
Coleman R L, Lorusso D, Gennigens C, et al. fficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology, 2021, 22(5): 609-619.
doi: 10.1016/S1470-2045(21)00056-5
|
|
|
[62] |
Bobrowicz M, Kubacz M, Slusarczyk A, et al. CD37 in B cell derived tumors-more than just a docking point for monoclonal antibodies. International Journal of Molecular Sciences, 2020, 21(24): 9531.
doi: 10.3390/ijms21249531
|
|
|
[63] |
Hicks S W, Lai K C, Gavrilescu L C, et al. The antitumor activity of IMGN529, a CD37-targeting antibody-drug conjugate, is potentiated by rituximab in non-Hodgkin lymphoma models. Neoplasia, 2017, 19(9): 661-671.
doi: 10.1016/j.neo.2017.06.001
|
|
|
[64] |
Wajant H. Therapeutic targeting of CD70 and CD27. Expert Opinion on Therapeutic Targets, 2016, 20(8): 959-973.
doi: 10.1517/14728222.2016.1158812
|
|
|
[65] |
Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends in Molecular Medicine, 2014, 20(6): 332-342.
doi: 10.1016/j.molmed.2014.02.007
|
|
|
[66] |
Detappe A, Mathieu C, Jin C N, et al. Anti-MUC1-C antibody-conjugated nanoparticles potentiate the efficacy of fractionated radiation therapy. International Journal of Radiation Oncology Biology Physics, 2020, 108(5): 1380-1389.
doi: 10.1016/j.ijrobp.2020.06.069
|
|
|
[67] |
Wu G, Li L, Qiu Y X, et al. A novel humanized MUC 1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer. Acta Biochimica et Biophysica Sinica, 2021, 53(12): 1625-1639.
doi: 10.1093/abbs/gmab141
|
|
|
[68] |
Vaisitti T, Arruga F, Vitale N, et al. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood, 2021, 137(24): 3365-3377.
doi: 10.1182/blood.2020008404
pmid: 33512452
|
|
|
[69] |
Hu E Y, Do P, Goswami S, et al. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood Advances, 2021, 5(16): 3152-3162.
doi: 10.1182/bloodadvances.2020003276
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|